Core Viewpoint - Nutex Health Inc. will release its financial results for the first quarter ended March 31, 2025, on May 13, 2025, and will discuss these results in a conference call on May 14, 2025 [1] Company Overview - Nutex Health Inc. is headquartered in Houston, Texas, and was founded in 2011. It operates as a healthcare management and operations company with two main divisions: Hospital Division and Population Health Management Division [3] - The Hospital Division owns, develops, and operates innovative healthcare models, including 24 micro-hospitals across 11 states [3] - The Population Health Management Division manages provider networks such as Independent Physician Associations (IPAs) and offers management and administrative support services to affiliated hospitals and physician groups [4]

Core Insights - Elanco Animal Health Incorporated reported financial results for Q1 2025, exceeding guidance for revenue, adjusted EBITDA, and adjusted EPS, with a 4% organic constant currency revenue growth and a revenue of $1,193 million, a decline of 1% year-over-year [2][4][7] - The company raised its 2025 revenue guidance to a range of $4,510 to $4,580 million, attributing the increase to favorable foreign exchange rates and strong performance in its diverse portfolio [2][19] - Elanco's adjusted net income for Q1 2025 was $184 million, or $0.37 per diluted share, reflecting a 9% increase compared to the same period in 2024 [15][19] Financial Performance - Q1 2025 revenue was $1,193 million, down 1% year-over-year, but showed a 4% organic constant currency growth [4][7] - Reported net income for Q1 2025 was $67 million, compared to $32 million in Q1 2024, with adjusted EBITDA at $276 million, a 6% decrease from the previous year [15][17] - The net leverage ratio as of March 31, 2025, was 4.4x adjusted EBITDA, with an improved year-end target of 3.9x to 4.3x [17][19] Business Segments - Pet Health revenue was $635 million, a decrease of 1% year-over-year, with a 1% increase when excluding foreign exchange impacts [8][9] - Farm Animal revenue was $546 million, down 2% year-over-year, but showed a 7% increase when excluding unfavorable impacts from the aqua divestiture and foreign exchange rates [9][10] - The company achieved approximately 10% dollar share of broad-spectrum sales in U.S. vet clinics for Credelio Quattro™ and over 35% penetration for Zenrelia™ in U.S. clinics [5][6] Guidance and Outlook - For the full year 2025, Elanco expects adjusted EBITDA of $830 to $870 million and adjusted EPS of $0.80 to $0.86, maintaining previous guidance despite macroeconomic uncertainties [19][21] - The company anticipates a revenue headwind of approximately $5 million in Q2 2025 due to unfavorable foreign exchange rates, but expects 4% to 6% organic constant currency revenue growth excluding these impacts [23][24] - Operating expenses are projected to increase by approximately 11% year-over-year in constant currency, driven by strategic investments in the innovation portfolio [23][24]

Financial Performance - Stella-Jones reported sales of CAD 773 million for Q1 2025, a slight decrease from CAD 775 million in Q1 2024, with pressure-treated wood sales down by CAD 36 million or 5% due to lower volumes across most product categories [4][6] - Gross profit for the quarter was CAD 168 million, resulting in a gross profit margin of 21.7%, down from 22.2% in the previous year [3][7] - Operating income increased to CAD 143 million, up from CAD 124 million in Q1 2024, aided by an insurance settlement of CAD 38 million [8][9] - EBITDA rose to CAD 179 million, with an EBITDA margin of 23.2%, compared to CAD 156 million and a margin of 20.1% in the same period last year [8][9] Acquisition Strategy - The company announced a definitive agreement to acquire Locweld Inc. for CAD 58 million, enhancing its infrastructure offerings in the steel transmission structure industry [2][14] - The acquisition is expected to unlock investment opportunities and create more value for customers and shareholders [2][14] Liquidity and Capital Resources - Stella-Jones maintained robust liquidity of CAD 691 million at the end of the quarter and a net debt-to-EBITDA ratio of 2.6x [10][32] - The company utilized its liquidity to support seasonal working capital needs, repurchase CAD 15 million of shares, and declared a dividend of CAD 17 million [10][13] Segment Performance - Utility poles sales increased to CAD 419 million, while railway ties sales decreased to CAD 208 million, reflecting a 14% decline in volumes [12] - Residential lumber sales remained stable at CAD 88 million, and industrial product sales increased to CAD 39 million [12]

SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2025. (All results compared to prior-year comparative period, unless otherwise noted)Q1 2025 Highlights and FY 2025 Outlook Revenue of $333.0 million increased 11% compared to revenue of $300.4 millionClinician base increased 10% to 7,535 clinicians, a sequential net inc ...

Core Viewpoint - Intchains Group Limited is set to release its unaudited financial results for the first quarter of 2025, which ended on March 31, 2025, highlighting its ongoing activities in altcoin mining, Ethereum-based cryptocurrency acquisition, and Web3 application development [1]. Group 1 - The earnings conference call will take place on May 22, 2025, at 8:00 PM U.S. Eastern Time, allowing stakeholders to discuss the financial results [2]. - Participants must register in advance using a provided link to receive dial-in numbers and a personal access PIN for the conference call [2]. - A live and archived webcast of the conference call will be available on the Company's investor relations website [3]. Group 2 - Intchains Group Limited focuses on providing altcoin mining products, acquiring and holding Ethereum-based cryptocurrencies, and developing innovative Web3 applications [4]. - For further inquiries, the Company has provided contact information for investor relations [5].

Core Insights - Agillic A/S reported a 4% increase in Annual Recurring Revenue (ARR) from subscriptions in Q1 2025 compared to Q1 2024, attributed to new clients and stabilization of churn [1][3] - Total revenue decreased by 1% year-over-year in Q1 2025, primarily due to lower revenue following a high churn level in the previous year, but is expected to increase in 2025 according to guidance [1][4] - EBITDA increased by 20% in Q1 2025 compared to Q1 2024, driven by reduced employee costs following organizational changes [2][3] Financial Performance - Revenue from subscriptions remained stable at DKK 12.6 million in Q1 2025, while revenue from transactions decreased by 5% to DKK 2.1 million [3] - Total revenue for Q1 2025 was DKK 14.7 million, down from DKK 14.8 million in Q1 2024, with a gross profit of DKK 12.0 million and a gross margin of 82% [3] - Employee costs decreased by 12% to DKK 7.6 million, while operational costs increased by 9% to DKK 3.6 million [3] Cash Flow and Financial Guidance - Cash flow from operations improved to DKK 1.9 million in Q1 2025, an increase of DKK 1.9 million year-over-year, attributed to positive developments in working capital [2][3] - The company maintains its financial guidance for 2025, expecting revenue between DKK 60-63 million, EBITDA between DKK 5-8 million, and ARR subscriptions between DKK 56-60 million [4]

Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), May 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The condensed co ...

Core Viewpoint - Valneva SE reported strong financial results for Q1 2025, with significant revenue growth and reduced operational cash burn, while confirming its financial guidance for the year [3][5][6]. Financial Performance - Total revenues for Q1 2025 were €49.2 million, a 50.3% increase from €32.8 million in Q1 2024 [5][6]. - Product sales reached €48.6 million, up 51.2% from €32.1 million in the same period last year [6][31]. - The company reported a net loss of €9.2 million compared to a net profit of €58.9 million in Q1 2024, which included €90.8 million from the sale of a Priority Review Voucher [6][45]. - Operating cash burn was reduced by 71% to €8.1 million in Q1 2025 from €28.4 million in Q1 2024 [6][47]. - Cash and cash equivalents stood at €153.0 million as of March 31, 2025, down from €168.3 million at the end of 2024 [6][50]. Product Sales and Market Developments - IXIARO®/JESPECT® sales increased by 65.5% to €27.5 million, driven by demand from travelers and the U.S. Department of Defense [10][32]. - DUKORAL® sales grew 9.4% to €12.3 million, supported by a supply agreement with the French government [12][33]. - IXCHIQ® sales surged to €3.0 million from €0.2 million in Q1 2024, with initial sales related to a chikungunya outbreak response [13][34]. - Third-party product sales increased to €5.8 million from €4.1 million, reflecting recovery from previous supply constraints [18][35]. Research and Development Highlights - Valneva is advancing its Lyme disease vaccine candidate, VLA15, with primary vaccinations completed and data expected by the end of 2025 [20][21]. - The company is also developing a tetravalent Shigella vaccine candidate, S4V2, with ongoing Phase 2 studies [23][24]. - A Phase 1 trial for a Zika vaccine candidate, VLA1601, is currently underway, with results anticipated this year [28][29]. Strategic Partnerships and Regulatory Progress - Valneva secured a $32.8 million supply contract for IXIARO® with the U.S. Department of Defense [7][11]. - The company received marketing authorization for IXCHIQ® in the UK and Brazil, marking significant milestones for its chikungunya vaccine [7][14][15]. - Valneva has entered into a licensing agreement with the Serum Institute of India to expand access to its chikungunya vaccine in Asia [15][61]. Financial Outlook - The company expects product sales to grow to €170-180 million in 2025, with total revenues projected to reach €180-190 million [6][5]. - R&D investments are anticipated to be between €90-100 million in 2025, partially offset by grant funding and tax credits [6][5].

Core Viewpoint - Integra LifeSciences Holdings Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and significant stock price decline [1][2][3]. Financial Performance - For Q1 2025, Integra reported earnings per diluted share of -$0.33, a decline from -$0.04 per diluted share in the same period last year [2]. - The company provided full-year earnings guidance and a second-quarter revenue outlook that fell significantly short of consensus estimates [2]. - Declines were noted in the Neurosurgery and Tissue Technologies segments, attributed to inventory issues and slower ordering patterns [2]. Stock Market Reaction - Following the announcement of the financial results, Integra's stock price dropped by $3.57 per share, or 21.19%, closing at $13.28 per share on May 5, 2025 [3].

Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its proprietary Binary Ionization Technology (BIT) platform [4] - The BIT solution employs a low percentage of hydrogen peroxide as its active ingredient, utilizing patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [4] - TOMI's products are applicable in various environments, including hospitals, biosafety labs, pharmaceutical facilities, schools, and commercial buildings [4] Financial Reporting - TOMI will report its first-quarter results for the period ending March 31, 2025, after the market closes on May 8, 2025 [1] - A conference call to discuss these results will be held at 4:30 p.m. ET on the same day [1] Participation Information - Participants can join the conference call by dialing (877) 545-0320 or (973) 528-0002 for international callers, using access code 616069 [2] - A replay of the teleconference will be available until May 22, 2025, with access codes provided for both domestic and international callers [3]